Drugs / Bifidobacterium longum
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06347770 | Jan 2024 → Mar 2028 expected | — | Zhe Li | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04082598 | Oct 2016 → Sep 2018 | — | Antonio Barone | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07184905 | Sep → Oct 2025 | — | Shenzhen People's Hospital | Completed | No outcome recorded |
| — | NCT06639516 | Feb → Dec 2025 overdue | acute pancreatitis | The First Affiliated Hospital of Nanchang University | Not yet recruiting | No outcome recorded |
| — | NCT04639141 | Dec 2021 → Apr 2022 | anxiety, autism spectrum disorder | The University of Queensland | Completed | No outcome recorded |
| — | NCT04706559 | Jan → Sep 2021 | atopic eczema | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| — | NCT06241222 | Jan 2018 → Dec 2021 | — | Third Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium longum | “After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105...” NCT06241222 ↗6“tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days + Bifidobacterium longum and Lactoferrin twice a day for 6days” NCT04082598 ↗ “received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd.” NCT06347770 ↗ “Bifidobacterium longum(BL)” NCT06639516 ↗ “Bifidobacterium longum” NCT04639141 ↗ |
| Modality | Other / unclassified | “Prebiotic + Probiotic” NCT04639141 ↗ |
| Route | Oral | “Mode of administration: oral.” NCT04639141 ↗ |